Furthermore, a potential role of IDE in the development of diabetes and Alzheimer’s disease might be addressed using insulin or amyloid-β peptide, respectively, that is not degraded by IDE but has a normal susceptibility to other degradation pathways [81,82,83,84]. This evidence concerns the gene INS and early-onset autosomal dominant Alzheimer disease.